Pfizer Inks Three Vyndamax Settlement Deals

Pfizer Inc. has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd to resolve patent infringement lawsuits in the U.S. District Court for the District of Delaware. These settlements extend the effective U.S. patent expiry date for VYNDAMAX (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM), to June 1, 2031, subject to other litigation outcomes. Previously, Pfizer anticipated a significant revenue decline for VYNDAMAX in 2029; however, these settlements now project stable revenues from 2028 through mid-2031. Pfizer Executive Vice President Aamir Malik highlighted the outcome as a recognition of the company's innovative science and patent strength, emphasizing the commitment to patients with ATTR-CM. VYNDAMAX remains the market leader with 75% of prescription volume, offering a once-daily capsule with proven benefits in reducing mortality and hospitalizations. Additionally, Pfizer has discontinued the supply of VYNDAQEL in the U.S., favoring VYNDAMAX as a single-capsule daily treatment for enhanced patient convenience.

(Source：Mirage News)